Therapeutic advances and future directions in Helicobacter pylori eradication
Frontiers in Microbiology · 03.12.2025 · 16
DOI: 10.3389/fmicb.2025.1652943 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Microbiology, online erschienen am 03.12.2025. Verfasst von Vidya Suresh und 5 weiteren Autor:innen. Beteiligte Einrichtung: Amrita School of Nanosciences and Molecular Medicine, Amrita Vishwa Vidyapeetham, Kochi, Kerala, India. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 112 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Helicobacter pylori (H. pylori) is a globally prevalent pathogen associated with a spectrum of gastrointestinal diseases, including chronic gastritis, peptic ulcer disease, and gastric malignancies. Although clarithromycin-based triple therapy continues to be effective in certain geographic areas, increasing global resistance highlights the need for treatment approaches tailored to local antibiotic susceptibility patterns. Recent clinical trials have shifted toward optimized quadruple regimens, particularly bismuth- and vonoprazan-based therapies, and resistance-guided treatment. Novel agents such as Rifasutenizol (TNP-2198) are entering phase 3 evaluation and show activity against multidrug-resistant strains. Adjunctive and alternative strategies including probiotics, phytochemicals, phage-derived enzymes, and nanoparticle-based delivery demonstrate synergistic effects in improving eradication and reducing antibiotic-associated adverse events. Multi-strain probiotic formulations and plant-derived compounds such as curcumin, catechins, and quercetin consistently suppress H. pylori virulence pathways and gastric inflammation in clinical and preclinical studies. This review provides an overview of current evidence from clinical trials and emerging therapeutic innovations, emphasizing balanced integration of conventional and next-generation approaches for sustainable global H. pylori management.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Amrita School of Nanosciences and Molecular Medicine, Amrita Vishwa Vidyapeetham, Kochi, Kerala, India.
- Department of Microbiology, Amrita Institute of Medical Sciences and Research Centre, Amrita Vishwa Vidyapeetham, Kochi, Kerala, India.
- Department of Gastroenterology and Hepatology, Amrita Institute of Medical Sciences and Research Centre, Amrita Vishwa Vidyapeetham, Kochi, Kerala, India.
Zitieren
APA
Suresh, V., Sreekumar, A., Kumar, A., Sadasivan, S., Biswas, R., & Biswas, L. (2025). Therapeutic advances and future directions in Helicobacter pylori eradication. Frontiers in Microbiology, 16. https://doi.org/10.3389/fmicb.2025.1652943
Vancouver
Suresh V, Sreekumar A, Kumar A, Sadasivan S, Biswas R, Biswas L. Therapeutic advances and future directions in Helicobacter pylori eradication. Frontiers in Microbiology. 2025;16. doi:10.3389/fmicb.2025.1652943
BibTeX
@article{Suresh2025,
author = {Suresh, Vidya and Sreekumar, Amritavarshini and Kumar, Anil and Sadasivan, Shine and Biswas, Raja and Biswas, Lalitha},
title = {Therapeutic advances and future directions in Helicobacter pylori eradication},
journal = {Frontiers in Microbiology},
year = {2025},
volume = {16},
doi = {10.3389/fmicb.2025.1652943}
}
EUVIMED